Homology joins BioMarin in halting gene therapy studies for rare metabolic disease
It was a tough week for companies, patients and families hoping a gene therapy for the rare metabolic disease phenylketonuria is on its way. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
